The FDA approved Nexlizet, according to an entry in its database of approved drugs. The new drug combines the active ingredient of Nexletol - which the FDA approved last week - with a generic non-statin drug, ezetimibe.
Executives from biopharma companies and an academic expert weigh in on what's in store for areas like cell and gene therapy, precision medicine and drug pricing.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Ann Arbor, Michigan, biopharmaceutical company Cerenis Therapeutics added $13.9 million to a July investment round that it will use to continue clinical trials of a drug to treat heart disease. Cerenis will use its latest investment to do Phase II clinical trial development of CER-001, which mimics high-density lipid ("good") cholesterol and can rapidly reverse atherosclerotic plaque.
The Cleveland Clinic will work with Esperion Therapeutics Inc. to develop “good cholesterol” therapies to fight cardiovascular disease. Privately held biopharmaceutical company Esperion in Plymouth, Mich. — which discovers, develops and commercializes therapies for cardiovascular diseases — announced its “collaborative research agreement” with the Clinic — the nation’s leading heart medical center — on Monday. […]
Esperion Therapeutics Inc., a spin-off from Pfizer Inc., has raised an additional $5 million to develop drugs that treat cardiovascular and metabolic disease, according to a SEC filing. The regulatory document states that Esperion has raised $27.75 million in equity and debt, but that dollar figure likely includes a $22.75 million Series A fundraise the company announced in 2008 after the spin-off.